Furthermore, targeting nAChR or DRD2 may be a potential therapeutic strategy to alter PD-1/PD-L1 pathway that can benefit those NSCLC patients who are refractory to immunotherapy. The gene discussed is DRD2; the disease is non-small cell lung carcinoma.